Effects of the anti-inflammatory drug salsalate on bone turnover in type 2 diabetes mellitus

Endocrine

Volumn 50, Issue 2, 2015, Pages 504-507

  Rubin, Mishaela R ^a   Goldfine, Allison B ^b   McMahon, Donald J ^a   Donovan, Daniel S ^a   Cremers, Serge ^a   Dworakowski, Elzbieta ^a   Schaefer, Ernst J ^c   Shoelson, Steven E ^b   Silverberg, Shonni J ^a  

^a Columbia University ^*  (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CARBOXY TERMINAL TELOPEPTIDE; GLUCOSE; HEMOGLOBIN A1C; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCALCIN; PLACEBO; SALSALATE; TARTRATE RESISTANT ACID PHOSPHATASE 5B; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; NONSTEROID ANTIINFLAMMATORY AGENT; SALICYLIC ACID DERIVATIVE;

ADULT; ANTIINFLAMMATORY ACTIVITY; BLOOD LEVEL; BONE MINERAL; BONE REMODELING; BONE TURNOVER; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; HUMAN; INFLAMMATION; LETTER; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEX DIFFERENCE; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOMARKERS; BONE REMODELING; DIABETES MELLITUS, TYPE 2; HUMANS; INFLAMMATION; OSTEOCALCIN; SALICYLATES; TREATMENT OUTCOME;

EID: 84945479267     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-015-0535-8     Document Type: Letter

References (18)

1. M. Janghorbani, R.M. Van Dam, W.C. Willett, F.B. Hu, Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am. J. Epidemiol. 166, 495–505 (2007)
2. L.J. Melton 3rd, B.L. Riggs, C.L. Leibson, S.J. Achenbach, J.J. Camp, M.L. Bouxsein, E.J. Atkinson, R.A. Robb, S. Khosla, A bone structural basis for fracture risk in diabetes. J. Clin. Endocrinol. Metab. 93, 4804–4809 (2008)
3. P. Vestergaard, Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes–a meta-analysis. Osteoporos. Int. 18, 427–444 (2007)
4. J.C. Krakauer, M.J. McKenna, N.F. Buderer, D.S. Rao, F.W. Whitehouse, A.M. Parfitt, Bone loss and bone turnover in diabetes. Diabetes 44, 775–782 (1995)
5. M. Yamamoto, T. Yamaguchi, K. Nawata, M. Yamauchi, T. Sugimoto, Decreased PTH levels accompanied by low bone formation are associated with vertebral fractures in postmenopausal women with type 2 diabetes. J. Clin. Endocrinol. Metab. 97, 1277–1284 (2012)
6. S.E. Shoelson, J. Lee, A.B. Goldfine, Inflammation and insulin resistance. J. Clin. Investig. 116, 1793–1801 (2006)
7. D. Cai, M. Yuan, D.F. Frantz, P.A. Melendez, L. Hansen, J. Lee, S.E. Shoelson, Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat. Med. 11, 183–190 (2005)
8. M.N. Weitzmann, S. Cenci, L. Rifas, J. Haug, J. Dipersio, R. Pacifici, T cell activation induces human osteoclast formation via receptor activator of nuclear factor kappaB ligand-dependent and -independent mechanisms. J. Bone Miner. Res. 16, 328–337 (2001)
9. P.J. Kostenuik, V. Shalhoub, Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr. Pharm. Des. 7, 613–635 (2001)
10. A.B. Goldfine, V. Fonseca, K.A. Jablonski, L. Pyle, M.A. Staten, S.E. Shoelson, The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann. Intern. Med. 152, 346–357 (2010)
11. M.J. Yin, Y. Yamamoto, R.B. Gaynor, The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396, 77–80 (1998)
12. A.B. Goldfine, R. Silver, W. Aldhahi, D. Cai, E. Tatro, J. Lee, S.E. Shoelson, Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin. Transl. Sci. 1, 36–43 (2008)
13. J.S. Manavalan, S. Cremers, D.W. Dempster, H. Zhou, E. Dworakowski, A. Kode, S. Kousteni, M.R. Rubin, Circulating osteogenic precursor cells in type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 97, 3240–3250 (2012)
14. A.G. Pittas, S.S. Harris, M. Eliades, P. Stark, B. Dawson-Hughes, Association between serum osteocalcin and markers of metabolic phenotype. J. Clin. Endocrinol. Metab. 94, 827–832 (2009)
15. Y. Bao, X. Ma, R. Yang, F. Wang, Y. Hao, J. Dou, H. He, W. Jia, Inverse relationship between serum osteocalcin levels and visceral fat area in Chinese men. J. Clin. Endocrinol. Metab. 98, 345–351 (2013)
16. S. Kiechl, J. Wittmann, A. Giaccari, M. Knoflach, P. Willeit, A. Bozec, A.R. Moschen, G. Muscogiuri, G.P. Sorice, T. Kireva, M. Summerer, S. Wirtz, J. Luther, D. Mielenz, U. Billmeier, G. Egger, A. Mayr, F. Oberhollenzer, F. Kronenberg, M. Orthofer, J.M. Penninger, J.B. Meigs, E. Bonora, H. Tilg, J. Willeit, G. Schett, Blockade of receptor activator of nuclear factor-kappaB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat. Med. 19, 358–363 (2013)
17. N. Napoli, E. Vittinghoff, N. Pannacciulli, D. Crittenden, J. Yun, A. Wang, R. Wagman, A.V. Schwartz, Effect of denosumab on fasting glucose concentrations in postmenopausal women with osteoporosis: results from subjects with diabetes or prediabetes from the FREEDOM trial. J. Bone Miner. Res. (2014)
18. S. Minisola, S. Dionisi, M.T. Pacitti, F. Paglia, V. Carnevale, A. Scillitani, S. Mazzaferro, G.S. De, J. Pepe, E. Derasmo, E. Romagnoli, Gender differences in serum markers of bone resorption in healthy subjects and patients with disorders affecting bone. Osteoporos. Int. 13, 171–175 (2002)